India’s largest pharmaceutical firm, Sun Pharmaceutical is reportedly scouting for a partner to market 14 brands it acquired from Novartis in Japan. In April, a wholly-owned subsidiary of the company, acquired 14 established prescription brands from Novartis AG and Novartis Pharma AG in Japan, for $293 million.
The acquired brands will be marketed by a local marketing partner under the Sun label. The local marketing partner will also be responsible for distribution of the brands.
Sun Pharmaceutical is the world’s fifth largest specialty generic pharmaceutical company and India’s top pharmaceutical company. Its global presence is supported by 49 manufacturing facilities spread across 6 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities.
